Blockade of Interferon-g Normalizes Interferon-Regulated Gene Expression and Serum CXCL10 Levels in Patients With Systemic Lupus Erythematosus

Arthritis and Rheumatology

Volumn 67, Issue 10, 2015, Pages 2713-2722

  Welcher, Andrew A ^a   Boedigheimer, Michael ^a   Kivitz, Alan J ^b   Amoura, Zahir ^c   Buyon, Jill ^d   Rudinskaya, Alla ^e   Latinis, Kevin ^f   Chiu, Kit ^a   Oliner, Kelly S ^a   Damore, Michael A ^a   Arnold, Gregory E ^a   Sohn, Winnie ^a   Chirmule, Narendra ^a   Goyal, Lovely ^a   Banfield, Christopher ^a   Chung, James B ^a  

^a AMGEN INC   (United States)

^b Altoona Center for Clinical Research   (United States)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DANBURY HOSPITAL   (United States)

^f UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 811; CHEMOKINE; CXCL10 PROTEIN, HUMAN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON; MONOCLONAL ANTIBODY;

ADULT; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; CHEMOKINE CXCL10; CHEMOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-GAMMA; INTERFERONS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84946589787     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/ART.39248     Document Type: Article

References (40)

1. Kotzin BL. Systemic lupus erythematosus. Cell 1996;85:303–6.
2. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358:929–39.
3. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003;100:2610–5.
4. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711–23.
5. Crow MK, George S, Paget SA, Ly N, Woodward R, Fry K, et al. Expression of an interferon-alpha gene program in SLE [abstract]. Arthritis Rheum 2002;46 Suppl:S281.
6. Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 2009;60:3098–107.
7. Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA, et al. Elevated serum levels of interferonregulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006;3:e491.
8. Lit LC, Wong CK, Tam LS, Li EK, Lam CW. Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis 2006; 65:209–15.
9. Narumi S, Takeuchi T, Kobayashi Y, Konishi K. Serum levels of IFN-inducible protein-10 relating to the activity of systemic lupus erythematosus. Cytokine 2000;12:1561–5.
10. Kong KO, Tan AW, Thong BY, Lian TY, Cheng YK, Teh CL, et al. Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus. Clin Exp Immunol 2009;156:134–40.
11. 1 T cells. J Exp Med 1993;178:1655–63.
12. Nguyen KB, Cousens LP, Doughty LA, Pien GC, Durbin JE, Biron CA. Interferon a/b-mediated inhibition and promotion of interferon g: STAT1 resolves a paradox. Nat Immunol 2000;1: 70–6.
13. Rayamajhi M, Humann J, Penheiter K, Andreasen K, Lenz LL. Induction of IFN-ab enables Listeria monocytogenes to suppress macrophage activation by IFN-g. J Exp Med 2010;207:327–37.
14. Hall JC, Casciola-Rosen L, Berger AE, Kapsogeorgou EK, Cheadle C, Tzioufas AG, et al. Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc Natl Acad Sci U S A 2012; 109:17609–14.
15. Chiche L, Jourde-Chiche N, Whalen E, Presnell S, Gersuk V, Dang K, et al. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol 2014;66: 1583–95.
16. Balomenos D, Rumold R, Theofilopoulos AN. Interferon-g is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest 1998;101:364–71.
17. 1 lupus-like nephritis with monoclonal antibody to g interferon. J Exp Med 1987;166:798–803.
18. Peng SL, Moslehi J, Craft J. Roles of interferon-g and interleukin-4 in murine lupus. J Clin Invest 1997;99:1936–46.
19. Hron JD, Peng SL. Type I IFN protects against murine lupus. J Immunol 2004;173:2134–42.
20. Seery JP, Carroll JM, Cattell V, Watt FM. Antinuclear autoantibodies and lupus nephritis in transgenic mice expressing interferon g in the epidermis. J Exp Med 1997;186:1451–9.
21. Harigai M, Kawamoto M, Hara M, Kubota T, Kamatani N, Miyasaka N. Excessive production of IFN-g in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B. J Immunol 2008;181:2211–9.
22. Karonitsch T, Feierl E, Steiner CW, Dalwigk K, Korb A, Binder N, et al. Activation of the interferon-g signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells. Arthritis Rheum 2009;60:1463–71.
23. Graninger WB, Hassfeld W, Pesau BB, Machold KP, Zielinski CC, Smolen JS. Induction of systemic lupus erythematosus by interferon-g in a patient with rheumatoid arthritis. J Rheumatol 1991;18:1621–2.
24. McBride JM, Jiang J, Abbas AR, Morimoto A, Li J, Maciuca R, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo- controlled, double-blind, dose-escalation study. Arthritis Rheum 2012;64:3666–76.
25. Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, Brohawn P, et al. Neutralization of interferon-a/b–inducible genes and downstream effect in a phase I trial of an anti– interferon-a monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009;60:1785–96.
26. Petri M, Wallace DJ, Spindler A, Chindalore V, Kalunian K, Mysler E, et al. Sifalimumab, a human anti–interferon-a monoclonal antibody, in systemic lupus erythematosus; a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 2013;65:1011–21.
27. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.
28. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
29. Symmons DP, Coppock JS, Bacon PA, Bresnihan B, Isenberg DA, Maddison P, et al, and Members of the British Isles Lupus Assessment Group (BILAG). Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Q J Med 1988;69:927–37.
30. Storey JD. A direct approach to false discovery rates. J R Stat Soc Ser B 2002;64:479–98.
31. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al, for the OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550–8.
32. Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 2008;48:1267–81.
33. Gupta S, Devanarayan V, Finco D, Gunn GR, Kirshner S, Richards S, et al. Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. J Pharm Biomed Anal 2011; 55:878–88.
34. Cui X, Churchill GA. Statistical tests for differential expression in cDNA microarray experiments. Genome Biol 2003;4:210.
35. Horwitz DA, Gray JD, Behrendsen SC, Kubin M, Rengaraju M, Ohtsuka K, et al. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthritis Rheum 1998;41:838–44.
36. Funauchi M, Sugishima H, Minoda M, Horiuchi A. Serum levels of interferon-g in autoimmune disease. Tohoku J Exp Med 1991; 164:259–67.
37. Akashi K, Hayashi S, Gondo H, Mizuno S, Harada M, Tamura K, et al. Involvement of interferon-g and macrophage colonystimulating factor in pathogenesis of haemophagocytic lymphohistiocytosis in adults. Br J Haematol 1994;87:243–50.
38. Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993;20:259–62.
39. Barrera P, Joosten LA, den Broeder AA, van de Putte LB, van Riel PL, van den Berg WB. Effects of treatment with a fully human anti-tumour necrosis factor-a monoclonal antibody on the local and systemic homeostasis of interleukin-1 and TNFa in patients with rheumatoid arthritis. Ann Rheum Dis 2001;60: 660–9.
40. Kackar RN, Harville DA. Approximations for standard errors of estimators of fixed and random effects in mixed linear-models. J Am Stat Assoc 1984;79:853–62.